SCHEDULE 13G/A: Citadel Entities Update Passive Stake in Lyra Therapeutics, Reporting 0.0% Beneficial Ownership
Beneficial Ownership Report
Citadel and its affiliated entities have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 0.0% in Lyra Therapeutics, Inc. as of December 31, 2024.
Summary
- This document is Amendment No. 2 to a Schedule 13G filing by various Citadel entities and Kenneth Griffin regarding their beneficial ownership in Lyra Therapeutics, Inc.
- The filing reports beneficial ownership as of December 31, 2024.
- Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin each report beneficial ownership of 21,083 shares of Lyra Therapeutics, Inc. Common Stock.
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC report 0 shares beneficially owned.
- All reporting persons, including Kenneth Griffin, hold a 0.0% stake in Lyra Therapeutics, Inc., based on 65,457,648 shares outstanding as of November 1, 2024.
- The filing explicitly states that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing (Schedule 13G) disclosing passive beneficial ownership, which does not inherently convey positive or negative sentiment regarding the company's operational performance or future prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by an institutional investor group and does not provide specific insights into broader industry trends or Lyra Therapeutics' competitive position within its sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding the passive ownership stake held by Citadel entities, confirming no intent to influence control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of 65,457,648 shares outstanding for Lyra Therapeutics, Inc. |
| 11/12/2024 | Date Lyra Therapeutics' Form 10-Q was filed, reporting shares outstanding. |
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end). |
| 02/14/2025 | Date of signing/filing of the Schedule 13G Amendment. |
Keywords
Lyra Therapeutics, Citadel, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.